TriangleNCT00783367 · OUTCOME
Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 3 months
What was measured
Response rate is defined as a complete response or partial response using anatomic criteria of the International Workshop Response Critieria (Cheson, 1999).
Groups in this outcome
Cohort 1
Revlimid + rituximab with dexamethasone
Cohort 2
Revlimid + rituximab (without dexamethasone)
| Group | Source count |
|---|---|
| Cohort 1 | 24 |
| Cohort 2 | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 | 14 | Not reported | Not reported | Not reported | Not reported |
| Cohort 2 | 13 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 13
- denoms
- counts
- group Id
- OG000
- value
- 24
- group Id
- OG001
- value
- 19
- units
- Participants
- description
- Response rate is defined as a complete response or partial response using anatomic criteria of the International Workshop Response Critieria (Cheson, 1999).
- groups
- description
- Revlimid + rituximab with dexamethasone
- id
- OG000
- title
- Cohort 1
- description
- Revlimid + rituximab (without dexamethasone)
- id
- OG001
- title
- Cohort 2
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 3 months
- title
- Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice